Form 4: Fennec Pharmaceuticals CFO Robert Andrade Acquires 2,431 Shares Through Restricted Stock Vesting
Insider Transaction Report
Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, has acquired 2,431 common shares through the vesting of previously awarded restricted stock, increasing his total beneficial ownership to 163,382 shares.
Summary
- Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals Inc. (FENC), acquired 2,431 common shares.
- The acquisition occurred on June 30, 2025, and represents shares released from restriction from awards granted on March 31, 2023, and May 16, 2024.
- The shares were acquired at a price of $0, indicating a vesting event rather than a purchase.
- Following this transaction, Robert Andrade beneficially owns a total of 163,382 common shares of Fennec Pharmaceuticals Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares through vesting indicates continued employment and alignment of the CFO's interests with the company's performance, which is generally viewed favorably, but it is not a discretionary purchase signaling strong conviction.
Positives
- The vesting of restricted shares for the Chief Financial Officer indicates continued alignment of management's interests with shareholders.
- It reflects the retention of key executive talent within the company.
Future Outlook
No forward-looking statements or guidance are provided in this document.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction and does not provide broader industry context or trends. It specifically details a change in beneficial ownership for a key executive at Fennec Pharmaceuticals.
Related Party Transactions
- The acquisition of 2,431 common shares by Robert Andrade, the Chief Financial Officer, through the vesting of restricted stock, constitutes a related party transaction.
Stakeholder Impact
- Shareholders: The transaction increases the direct beneficial ownership of a key executive, potentially aligning management's interests more closely with shareholder value. It provides transparency regarding insider holdings.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date of initial restricted share award to Robert Andrade. |
| 05/16/2024 | Date of additional restricted share award to Robert Andrade. |
| 06/30/2025 | Transaction date when 2,431 common shares were released from restriction and acquired by Robert Andrade. |
| 07/01/2025 | Date the Form 4 filing was signed by Robert Andrade. |
Keywords
Fennec Pharmaceuticals, FENC, Robert Andrade, CFO, Insider Transaction, Form 4, Share Vesting, Restricted Stock, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.